Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Beth Israel Deaconess Medical Center |
---|---|
Information provided by: | Beth Israel Deaconess Medical Center |
ClinicalTrials.gov Identifier: | NCT00794911 |
The main purpose of this study is to determine whether psychological intervention is effective in improving quality of life, mood, and relationships among adults with hepatitis C virus and cirrhosis awaiting liver transplantation.
Condition | Intervention |
---|---|
Chronic HCV |
Behavioral: Quality of Life Therapy Behavioral: Supportive Therapy |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation |
Estimated Enrollment: | 75 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
QOLT: Experimental
Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
|
Behavioral: Quality of Life Therapy
8 weekly individual counseling sessions
|
ST: Active Comparator
Supportive Therapy (ST) 8 weekly individual counseling sessions
|
Behavioral: Supportive Therapy
8 weekly individual counseling sessions
|
Standard Care: No Intervention |
Quality of life (QOL) outcomes are important to all stakeholders in liver transplantation. For patients with end-stage liver disease, QOL is significantly compromised and more data about QOL allows them to make an informed risk-benefit analysis in deciding whether to pursue transplantation. The long-term goal of this research program is to better understand how QOL can be enhanced, to identify the mechanisms underlying QOL changes, to identify which patients benefit most from QOL intervention, and to determine whether QOL benefits can extend beyond transplantation. The objective of this research is to determine the effectiveness, feasibility and applicability of Quality of Life Therapy (QOLT) in treating adults with hepatitis C virus and cirrhosis awaiting liver transplantation. In a recent small, single-center clinical trial, we demonstrated that QOLT can improve QOL, psychological functioning, and social intimacy in patients awaiting lung transplantation. We now seek to examine whether this intervention can be effectively adapted and implemented with adults with hepatitis C virus and cirrhosis awaiting liver transplantation. The central hypothesis is that by targeting improvements in specific life domains, QOLT yields significant clinical benefits in QOL, psychological functioning, and the patient-caregiver relationship. This hypothesis is being tested by pursuing three specific aims: 1) Determine the effectiveness of QOLT; 2) Examine the differential effectiveness of QOLT by race (White, African American); and 3) Assess the feasibility of a multisite R01 application. Under the first aim, adults with hepatitis C virus and cirrhosis awaiting liver transplantation are being randomized to receive QOLT, Supportive Therapy (ST), or Standard Care (SC). Primary outcomes are changes in QOL, psychological functioning, and social intimacy at 1 and 12 weeks post-treatment. Under the second aim, the relationship between race and intervention outcomes will be closely examined. Under the third aim, attrition rates, reasons for attrition, therapist adherence to treatment protocols, and participant satisfaction ratings are being gathered to assess the need for protocol changes prior to developing a larger, multisite clinical trial R01 application. This study is innovative because it is among the first to evaluate a theoretically-driven psychological intervention to specifically improve QOL in the context of hepatitis C virus and cirrhosis and liver transplantation. The research is significant because it is expected to advance and expand understanding of how QOL can be improved in patients with hepatitis C virus and cirrhosis.
Ages Eligible for Study: | 21 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: James R Rodrigue, Ph.D. | 617-632-9700 | jrrodrig@bidmc.harvard.edu |
Contact: Michael P Curry, MD | 617-632-9700 | mcurry@bidmc.harvard.edu |
United States, Massachusetts | |
Beth Israel Deaconess Medical Center | Recruiting |
Boston, Massachusetts, United States, 02215 | |
Contact: James R Rodrigue, Ph.D. 617-632-9700 jrrodrig@bidmc.harvard.edu | |
Contact: Michael P Curry, MD 617-632-9700 mcurry@bidmc.harvard.edu | |
Sub-Investigator: Doug W Hanto, MD, PhD | |
Sub-Investigator: Michael P Curry, MD |
Principal Investigator: | James R Rodrigue, Ph.D. | Beth Israel Deaconess Medical Center |
Responsible Party: | Beth Israel Deaconess Medical Center ( James R. Rodrigue, PhD ) |
Study ID Numbers: | 2007P-000171 |
Study First Received: | November 19, 2008 |
Last Updated: | December 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00794911 |
Health Authority: | United States: Federal Government; United States: Institutional Review Board |
Liver Transplantation Quality of Life Chronic HCV |
Hepatitis C Virus Cirrhosis Liver disease |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases Fibrosis |
Quality of Life Hepatitis, Viral, Human Liver Cirrhosis Hepatitis C |
RNA Virus Infections Pathologic Processes Flaviviridae Infections |